Project Grant K99CA296777
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$102K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $202,982 to Cold Spring Harbor Laboratory (CSHL) for research to understand and target inflammation in clonal hematopoiesis (CH). The research aims to: 1) identify inflammatory mediators of CH-mutant hematopoietic stem and progenitor cells (HSPCs) and evaluate their potential as therapeutic targets; and 2) uncover the transcriptional and epigenetic mechanisms by which age-related...
The National Cancer Institute (NCI) awarded a $220,018 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to the University of Louisville. The grant will fund research to determine whether chemotherapy-induced changes in mitochondrial function and dynamics in hematopoietic stem and progenitor cells (HSPCs) contribute to the development of pro-metastatic myeloid cells. The study aims to investigate the role of mitochondrial reactive oxygen species (ROS) production and...
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
The National Cancer Institute (NCI) awarded a $188,749 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Vanderbilt University to study the impact of clonal hematopoiesis of indeterminate potential (CHIP) on the tumor microenvironment and clinical outcomes in triple negative breast cancer (TNBC). The grant aims to leverage clinical sequencing data, patient samples, mouse models, and ex vivo experiments to define CHIP as a prognostic biomarker for TNBC and determine how...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
This federal Project Grant award, valued at $166,644.00 and awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the functional and molecular consequences of aging and TET2 mutations on human hematopoietic stem cell responses to inflammatory cytokines like IL-1β. The research aims to provide a comprehensive understanding of how these factors alter inflammatory response pathways, leading...
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,220,394 project grant to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on September 15, 2024, will fund research to comprehensively characterize the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The research aims to investigate the molecular...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...